The metabolic health market is currently witnessing a capital migration of historic proportions. If we look at the numbers, the […]

The Economic Reality of the Patent Cliff The pharmaceutical industry is currently facing a structural shift in how it calculates

The global pharmaceutical sector is currently confronting a revenue transition of unprecedented scale, characterized by the convergence of the most

The pharmaceutical sector faces a revenue contraction of $236 billion through 2030 as blockbuster patents expire. This contraction is a

The patent cliff is not a metaphor. It is a calendar event. A specific date — often visible years in

Introduction: Why Germany Matters More Than Ever For years, the narrative surrounding Germany was one of caution. A powerful but

The specialty pharmaceutical market is undergoing a structural realignment as high-value biologics and small molecules face their first wave of

The Patent Strategy That Keeps Failing Biologic drug developers have spent decades trying to own entire therapeutic concepts. Claim the

Why Five Years Is the Only Number That Matters in Pharma When Pfizer’s patent on Lipitor expired in November 2011,